Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for noncirrhotic nonalcoholic ...

The new medication, Madrigal Pharmaceuticals’ resmetirom ... and Madrigal must complete a post-approval study to verify the drug’s clinical benefit. “I believe this approval milestone ...

but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. The Massachusetts company has reported the results of the phase 3 MAESTRO ...

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat ... s oral THR β-selective agonist Rezdiffra (resmetirom) for adults with MASH – also known as non ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...

Rezdiffra received U.S. FDA approval as the first and only treatment ... risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action; enrollment and trial conclusion ...

Resmetirom, the first drug approved by US-FDA for the management of MASH, was used as positive control at an oral dose of 3.0 mg/kg once a day for 3 weeks. Thykamine™ administered orally ...

Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist. Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis (NASH).